Prime Editing: A New Genome Engineering Paradigm and Its Intellectual Property Implications
Prime editing represents a significant technological advance in genome engineering, combining the programmability of CRISPR systems with the precision of reverse transcription–mediated DNA synthesis. First reported in 2019 and refined through subsequent generations (PE2, PE3, PE5, and PEmax), prime editing offers the ability to install targeted substitutions, insertions, and deletions without introducing double-strand breaks (DSBs)…
Life Biosciences Patent Analysis: Partial Epigenetic Reprogramming
This report provides a comprehensive analysis of Life Biosciences’ key patent, US Patent No. 12,252,518, including claim summaries, plain-language interpretation, comparison with competitors (Turn Bio, NewLimit, Altos Labs), mapping of their partial epigenetic reprogramming (PER) platform, and freedom-to-operate considerations. 1. Claim Language The granted patent US 12,252,518 B2, titled “Methods of treating non-arteritic anterior ischemic…
AAV Vector Encoding FXN for Friedreich’s Ataxia
Assignee: Cornell University & collaborators (licensed to Lexeo Therapeutics, Inc.)Example Patent: US 9,066,966 B2 (Representative patent in the licensed family)Filing / Priority: Before 2012 (priority dates back to foundational frataxin gene therapy work)Issued: 2015–2016 (example patent grant date for US 9,066,966 B2)Expiration: ~2033 (subject to adjustment and maintenance) What This Patent Covers This patent family broadly protects adeno‑associated viral…
BioTech IP Review 